Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was up 16.3% on Thursday . The stock traded as high as C$0.28 and last traded at C$0.25. Approximately 610,571 shares traded hands during mid-day trading, a decline of 2% from the average daily volume of 621,060 shares. The stock had previously closed at C$0.22.
Hemostemix Stock Up 12.7 %
The firm has a market cap of C$27.01 million, a P/E ratio of -15.50 and a beta of 0.20. The firm’s fifty day moving average is C$0.11 and its two-hundred day moving average is C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- 3 Healthcare Dividend Stocks to Buy
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- How to Short a Stock in 5 Easy Steps
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Basic Materials Stocks Investing
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
